Category: pharma & healthcare

Long COVID symptoms, such as fatigue, difficulty breathing, and brain fog, may be a consequence of damage to the vagus nerve.

A small clinical trial demonstrates encouraging early results using an adopted version of CAR T therapy to treat patients with rare autoimmune disorder myasthenia gravis.

A recent study by revealed a link between bacterial blooms of the gut bacterium Ruminococcus blautia gnavus and flare-ups of disease in women with Lupus Nephritis.

A drug called bulevirtide marks the first treatment option available to hepatitis D patients since the discovery of the virus in 1977. Real-world results are promising.

The increasing numbers of cell and gene therapy pipeline candidates, along with a steady growth of new approvals, are stretching manufacturing capacity to its limits.

This essay delves into the transformative impact of anti-VEGF agents on “wet” age-related macular degeneration.

A recent paper brings us closer to creating an accurate model of the lungs. This progress may lead to a deeper understanding of lung diseases and how they can be treated.

A new textile electronic system will allow for the free-form manufacturing of smart fabrics to a degree previously unreached.

The typical American’s willingness to pay amount for the new obesity drugs appears to be quite low in relation to the actual list prices, or even payer co-insurance.

As the first therapeutically interchangeable Humira-referenced biosimilar Cyltezo may gain a distinct marketing advantage over competitors.